The purpose of this study is to determine the efficacy, safety, tolerability, and
pharmacokinetics (PK) of meropenem-vaborbactam compared to piperacillin/tazobactam for 7 to
14 days in the treatment of hospitalized adults who meet clinical, radiographic, and
microbiological criteria for hospital-acquired bacterial pneumonia (HABP) or
ventilator-associated bacterial pneumonia (VABP).